Daily low-dose aspirin doesn’t reduce heart-attack risk in healthy people from shutterstock.com John McNeil, Monash University Taking low-dose aspirin daily doesn’t preserve good health or delay the onset of disability or dementia in healthy older people. This was one finding from our seven-year study that included more than 19,000 older people from Australia and the…
Details
ASPREE-XT: follow-up aspirin & ageing research Thanks to a funding boost from the NIA (National Institute on Aging), we are delighted to announce that study visits will continue in 2018 as part of the new ASPREE-XT ( XT is shortened for eXTension) study. A staggering 95% of ASPREE participants had indicated, prior to the…
Details
It seems 2017 was the year of the study updates! We’ve not quite been everywhere – but we have held study updates in many places this year. And it’s been fun. From Wollongong to Burnie, members of our team were delighted to meet thousands of ASPREE participants and guests during 24 presentations held across…
Details
Elderly patients taking daily aspirin after a stroke or MI (heart attack) should be given PPIs (Proton Pump Inhibitors) to reduce the risk of bleeding according to a Lancet study of 3166 patients, which found the risk of internal bleeding is far higher than was previously thought.
Details
Head Office Moves Across Road The ASPREE National Co-ordinating Centre recently moved to the Alfred Centre, located across the road from our old office. After seven years on the ground floor, the Melbourne team is being treated to impressive views of Fawkner Park! It is important to note that our email and phone details have not changed and…
DetailsASPREE Ballarat team moves to new site in Wendouree Last month ASPREE Study Co-ordinators Sussan Conway and Theresa Grice relocated to their new office at the Ballarat Allergy Clinic, 1011 Howitt Street, Wendouree. ASPREE sincerely thanks Dr Harry Zehnwirth and his team for the warm welcome to the building. Telephone contact details for Sussan and…
Details
US ASPREE collaborators and NCI guests visit Melbourne. Earlier this month we welcomed our US research collaborators from the Berman Center for Outcomes and Clinical Research, along with guests from the National Cancer Institute (NCI), to discuss the progress and future of the ASPREE trial and sub-studies. The Berman Center for Outcomes and Clinical Research co-ordinates…
Details
Prof Chris Reid shares 30 years experience in medical research Professor Chris Reid is a Director of the Monash Centre of Cardiovascular Research and Education (CCRE) in Therapeutics, Monash University. He is also a senior investigator in the ASPREE trial. In this video, produced by Australia’s peak medical research funding body the NHMRC, Chris explains ‘public…
Details
ASPREE study funding announcement The ASPREE study received more than $5.5 million in the latest round of National Health and Medical Research Council (NHMRC) grants announced by Minister for Health and Aged Care, Hon Sussan Ley, at Monash University on 3rd December 2016. The ASPREE Completion Project, awarded $4.8 million, and the aspirin in prevention…
DetailsHats off to our perceptive ASPREE participants! Sincere thanks to our eagle-eyed participants for advising of the misprinted phone number on the back page of the latest ASPREE ‘The Tablet’ newsletter. …
Details© 2015 All Rights Reserved. • Monash University, Department of Epidemiology and Preventive Medicine | Disclaimer & Privacy